Int. J. Pharm. Investigation, 2020;10(4):590-593 International Journal of Pharmaceutical Investigation, Vol 10, Issue 4, Oct-Dec, 2020 590 Original Article Efcacy of Sitagliptin Versus Glimepiride 1-3 mg for Treatment of Type-2 Diabetes Patients Bhaskar Joshi 1 , Praveen Yadav, Annabathini Geetha Bhavani 1,2, * 1 Department of Chemistry, Noida International University, Gautama Buddha Nagar, Greater Noida, Uttar Pradesh-203201, INDIA. 2 Noida International University Research Innovation Centre, Noida International University, Gautama Buddha Nagar, Greater Noida-203201, Uttar Pradesh, INDIA. ABSTRACT Objectives: This study is to compare the effect of Sitagliptin and Glimepiride 1-3mg as a combination therapy for type-2 diabetes mellitus patient’s treatment. It is also concern to evaluate the effect of low dosage on type-2 diabetes mellitus patients as an antidiabetic drug. Methods: The type-2 diabetes patient’s clinical data was analyzed during the treatment through the inclusion and exclusion selection methods. The samples of Sitagliptin (1-3 mg) as add on therapy were chosen by open label study by randomization on type-2 diabetes mellitus. The total 45 patients (n=45) with age group between 20-60 years was received for statistical analysis. The samples are screened by inclusion with the baseline of HBA1c was ≥7.0 % and ≤ 10.5 % was selected. The exclusion criteria are restricted to upper age limit of 60 years and having the symptoms of chronic kidney, hepatic, malignancy. Results: The data of combination therapy is compared with initial data and after 14 weeks of treatment data is considered for the effect of antidiabetic drugs. The statistic results show with greater improvement in HbA1c value and total daily dose of insulin were achieved with Sitagliptin compared to Glimepiride therapy. Concluscion: Finally, Sitagliptin 100mg is an add-on to Metformin treatment shows more adequate results with better tolerance on type-2 diabetes with satisfactory glycemic control is found to be signifcant reduction with daily dose of insulin in the body. Key words: Ef fcacy, Sitagliptin, Glimepiride1-3mg, HbA 1c value, Type-2 diabetes mellitus. Correspondence Dr. A Geetha Bhavani 1 Department of Chemistry, Noida International University, Gautama Buddha Nagar, Greater Noida, Uttar Pradesh-203201, INDIA. 2 Noida International University Research Innovation Centre, Noida International University, Gautama Buddha Nagar, Greater Noida-203201, Uttar Pradesh, INDIA. Phone no: +918826699428 Email: ageethabhavani@gmail.com DOI: 10.5330/ijpi.2020.4.103 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. INTRODUCTION Type-2 diabetes mellitus (T2DM) is found to be silently chronicle and numbers are increasing day by day globally. Te world health organization estimates 415 million patients with T2DM globally, which may escalate to 642 million by 2040. 1 T2DM is characterized by elevated plasma glucose levels, blood glucose fasting, blood sugar post prandial and glycosylated hemoglobin and type-2 diabetes (T2D) accounts for most patients associated with diabetes mellitus. Te risk of acquiring T2D is determined by a combination of environmental factors and genetic susceptibility. Te T2DM is well known treatment with both oral and injectable, among oral drugs well prescribed as a painless and equally efective. Metformin is the frst-line of treatment for type-2 diabetes mellitus patients. Metformin and sulfonylureas (SU) is the commonly used oral antidiabetic agents and mostly physician start with frst line of treatment to ensure the patient is diabetic or non-diabetic. However, few side efects are noticed with SU drugs subjection are multiple changes like increase hypoglycaemia and weight gain. Te physicians do not recommend the usage of SU drugs as they are associated with many limitations. Te combination therapy is well practiced as they do not evident any side efects on patients and patients will ultimately require to be shifed to another class of oral antidiabetic agents or insulin therapy. 2,3 Te class of oral antidiabetic drugs also DPP-4 inhibitors to enhance function of endogenous incretin and helps with glucose homoeostasis without increasing the risk of hypoglycaemia and weight gain 4,5 due to the multiple action on Sitagliptin such as anti-infammatory, efect on monocytes and T-lymphocytes are the clinical usefulness of the addition of Sitagliptin in T2DM could beyond glycemic reduction. Te secondary efects like prevention of weight gain, may be expected from the addition of Sitagliptin to diabetes treatment. 6,7 Tis study was made to evaluate the medication like Metformin and Sitagliptin over the T2DM patients through statistical analysis. METHODOLOGY Tis study deign was on open label system on enrolled T2DM patients in the duration of 1 st September 2017 to 30 th September 2019 in Felix Hospital, Noida, U.P. India. Te ethical committee was approved to analyze the patients undergoing the treatments for T2DM with registration number of NERB/SOS/CHEM/18/106 from patients data stored in hospital records (supporting information). All the T2DM patients are given the written consent for data analysis and results publication (supporting information). Te main subjects of study were gender specifc and age between 20 to 60 years or older group with passable monitored glucose level by glycosylated hemoglobin (HbA1c) test of ≥7.0 % and ≤ 10.5 %. Afer 14 th weeks of treatment with Sitagliptin and Glimepiride on T2DM patients, the HbA 1c was monitored and compared with previous results. Figure 1 represents the fowchart of present study on efect of Sitagliptin and Glimepiride on T2DM patients. For this study the data of T2DM patients with symptoms of (i) any history of ketosis, (ii) any surgical treatment for severe infections, (iii) any symptoms of renal disease (serum creatinine level >1.6 mg/dl), (iv) any history with malignancy and hepatic and (v) any history of allergy or pregnancy was excluded. 7,8 Te statistical analysis based on numerical data collected with patients’ drug treatments. Te